<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>20920852</identifier>
<setSpec>0214-753X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Blasco Cordellat, A</dc:author>
<dc:author>Camps Herrero, C</dc:author>
<dc:author>Caballero Díaz, C</dc:author>
<dc:description xml:lang="en">Cancer is a disease of high incidence, which determines that the health systems will be forced to allocation a significant amount of resources. In an era of evidence-based medicine and increasing cost pressures, it is important to understand the relative clinical and economic impact of the many drug treatment strategies available for cancer patients. Currently, resources that may be spent in pharmacoeconomics expenditure are limited so it is necessary to rationalize their consumption and priorize in the allocation of these resources to the options with higher economic advantages. Pharmacoeconomic studies will permit us to know what is the efficiency of different therapeutic alternatives so they will help to determine the therapeutic options that we should use in routine medical practice.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2010 Mar </dc:date>
<dc:title xml:lang="es">Farmacoeconomía y los costes de los medicamentos contra el cáncer.</dc:title>
<dc:title xml:lang="en">[Pharmacoeconomics and cost of cancer drugs].</dc:title>
<dc:publisher>Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</dc:publisher>
</metadata>
</record>
</pubmed-document>
